Immunovant (IMVT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.22 (+0.77%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Immunovant (IMVT)
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Key Insights

Critical company metrics and information
  • Share Price

    $28.62
  • Market Cap

    $4.20 Billion
  • Total Outstanding Shares

    146.79 Million Shares
  • Total Employees

    207
  • Dividend

    No dividend
  • IPO Date

    June 21, 2019
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.immunovant.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Exchange Gains/Losses$1.05 Million
Net Cash Flow From Financing Activities, Continuing$730000.00
Net Cash Flow From Investing Activities, Continuing$196000.00
Net Cash Flow From Investing Activities$196000.00
Net Cash Flow From Operating Activities$-88.65 Million
Net Cash Flow, Continuing$-88.11 Million
Net Cash Flow$-87.06 Million
Net Cash Flow From Operating Activities, Continuing$-88.65 Million
Net Cash Flow From Financing Activities$730000.00

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Diluted Earnings Per Share$0.74
Net Income/Loss Attributable To Parent$-109.12 Million
Net Income/Loss Available To Common Stockholders, Basic$-109.12 Million
Preferred Stock Dividends And Other Adjustments$0.00
Basic Average Shares$146.47 Million
Operating Expenses$115.74 Million
Basic Earnings Per Share$0.74
Diluted Average Shares$146.47 Million
Net Income/Loss$-109.12 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income Tax Expense/Benefit$78000.00
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations After Tax$-109.12 Million
Income/Loss From Continuing Operations Before Tax$-109.04 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Equity Attributable To Parent$449.05 Million
Liabilities$66.65 Million
Noncurrent Liabilities$0.00
Fixed Assets$671000.00
Accounts Payable$20.73 Million
Other Non-current Assets$7.66 Million
Current Liabilities$66.65 Million
Prepaid Expenses$32.55 Million
Liabilities And Equity$515.71 Million
Equity$449.05 Million
Other Current Liabilities$45.93 Million
Other Current Assets$474.82 Million
Current Assets$507.37 Million
Equity Attributable To Noncontrolling Interest$0.00
Assets$515.71 Million
Noncurrent Assets$8.34 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.